Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4’s Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company.
Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (Nasdaq: MGTA), a biotechnology company focused on developing novel medicines for patients with autoimmune diseases and blood cancers. Prior to that, he was Chief Financial Officer of Foundation Medicine, a molecular information company, helping lead the business through early development, its initial public offering, subsequent growth into a global commercial organization, and ultimately its acquisition by Roche Holdings (Nasdaq: RHHBY). Previously, Mr. Ryan led the finance and strategic planning functions of several other high growth life science companies.
“Jason brings to Sema4 outstanding leadership experience in the life sciences and biotechnology sectors, and an impressive background in finance and scaling businesses,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “We expect that Jason will be an invaluable addition to Sema4 as we transition to becoming a publicly traded company, and we are delighted to have the opportunity to leverage his expertise in support of our mission to advance healthcare through data-driven insights.”
In addition to Sema4, Mr. Ryan currently serves on the board of directors of Singular Genomics (Nasdaq: OMIC) and previously served on the board of directors of ArcherDX, Inc. (acquired by Invitae (NYSE: NVTA)). He began his career at Deloitte & Touche where he earned a CPA, and received a B.A. in Economics from Bates College and an M.B.A. from Babson College.
“Sema4 has built a unique data ecosystem and platform to drive precision medicine into the standard of care,” said Mr. Ryan. “I’m thrilled to join Sema4’s Board of Directors at such an exciting time for the company. I look forward to working with the team to help us further improve the diagnosis, treatment, and prevention of disease.”
Mr. Ryan will be one of four new members of Sema4’s Board of Directors after the company completes its business combination with CM Life Sciences. Mr. Ryan joins the previously announced additions of Nat Turner, co-founder of Flatiron Health (a Roche company), Emily Leproust, Chief Executive Officer of Twist Biosciences (Nasdaq: TWST), and Eli Casdin, Chief Investment Officer of Casdin Capital.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
